Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook

Stock Track

2025/03/05

BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.

The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:

37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million
31% year-over-year increase in total Q4 2024 revenue to $22.7 million
Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023
Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023
Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023

The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1186348054"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186348054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186348054?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186348054","market":"hk","top_or_hot":-1,"title":"Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook","media":"Stock Track","content":"<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-03-05 02:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLFS","symbol_name":"BioLife Solutions Inc.","start_time":0,"source_url":"","article_id":"1186348054","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186348054","pubTimestamp":1741111832,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioLife Solutions  stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:. 37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million. 31% year-over-year increase in total Q4 2024 revenue to $22.7 million. Improved GAAP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLFS":"BioLife Solutions Inc."},"translate_title":"股票赛道BioLife Solutions在强劲的第四季度盈利和积极的2025年前景后飙升5.10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":1},"content_text":"BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.\nThe life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n\n37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million\n31% year-over-year increase in total Q4 2024 revenue to $22.7 million\nImproved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023\nPositive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023\nNarrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023\n\nThe company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}